Previous 10 | Next 10 |
AMES, Iowa, Oct. 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its third quarter 2019 conference call and webcast at 8:30 AM ET on Wednesday, November 6, 2019, to discuss its third quarter financial results and provide an updat...
AMES, Iowa, Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a conditional marketing...
Minerva Neurosciences (NASDAQ: NERV ) -25% following delay in schizophrenia drug results. More news on: Minerva Neurosciences, Inc., Pacific Coast Oil Trust, TD Ameritrade Holding Corporation, Stocks on the move, Read more ...
NewLink (NASDAQ: NLNK ) and Lumos Pharma sign a definitive merger agreement that will result in Lumos becoming a wholly-owned subsidiary and NewLink taking on the Lumos name and new "LUMO" ticker. More news on: NewLink Genetics Corporation, Tech stocks news, Healthcare stocks n...
-- Combined company to assume the name, Lumos Pharma, Inc. and is expected to be led by Richard J. Hawkins, current CEO of Lumos Pharma -- -- Lumos asset, LUM-201, represents first oral therapeutic candidate for pediatric growth hormone deficiency (PGHD) with planned Phase 2b expected...
SPI Energy (NASDAQ: SPI ) +60% on the launch of its newly established hemp and CBD business. More news on: SPI Energy Co., Ltd., DAVIDsTEA Inc., Sintx Technologies, Inc., Stocks on the move, Read more ...
NewLink Genetics (NASDAQ: NLNK ) +14.6% after-hours on news that the U.S. Food and Drug Administration accepted the Biologics License Application and granted priority review for partner Merck's V920 investigational ebola vaccine. More news on: NewLink Genetics Corporation, Healthcare s...
AMES, Iowa, Sept. 17, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Merck’s Biologics License Application (BLA) and granted priority review for the investigational Ebola vaccine ...
NewLink Genetics (NASDAQ: NLNK ): Q2 GAAP EPS of -$0.27 beats by $0.02 . More news on: NewLink Genetics Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
AMES, Iowa, July 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink Genetics” or the “Company”) today announced financial results for the second quarter ended June 30, 2019 and provided an update on clinical and corporate develo...
News, Short Squeeze, Breakout and More Instantly...
Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock PR Newswire NEW ORLEANS ...
AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the appointment of Joseph S. McCracken, DVM, MS to the company's Board of Directors, effective March 23...
- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash ...